Bringing the fundamentals into focus…
Back to Protara Therapeutics, Inc.
How Protara Therapeutics, Inc. stacks up
TARA · against 149 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #70 of 150 · scores higher than 38% of peers
Bars: peers in each 10-point band of the valuation score35 peers with a valuation score of 30–39, including TARA · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -56.4% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -46.7% vs peer median 0.0%
Metric by metric
Position: dot = TARA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TARA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 134 reported | -56.4% | -10.4% | 23% | 30% | |
| EBITDA yieldHigher is better · 157 reported | -3652.8% | 1.7% | 3% | 50% | |
| Free cash flow yieldHigher is better · 102 reported | -46.7% | -16.3% | 23% | 20% | |
| Book yieldHigher is better · 137 reported | 113.3% | 72.3% | 67% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around TARA| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 70 | 149M USD | 33 | ||
| 70 | 191M USD | 33 | 38 | |
| 70 | 165M USD | 33 | 50 | |
| 70 | 158M USD | 33 | 14 | |
| 70 | 142M USD | 33 | 45 | |
| 70 | 89M USD | 33 | 31 | |
| 70 | 184M USD | 33 | 33 | |
| 70 | 186M USD | 33 | 52 | |
| 95 | 171.0B KRW (≈$123M) | 32 | 41 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score